Science and Technology

Author Archive | xchem-editor

June 11, 2020

Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease

WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, […]

Continue Reading
June 3, 2020

GHO Capital Acquires X-Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman LLC.

Continue Reading
May 20, 2020

X-Chem Announces Licensing of a Drug Discovery Program to Otsuka

Waltham, Mass – May 20, 2020 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has licensed a drug discovery program from X-Chem.

Continue Reading
February 6, 2020

ALK-Abelló and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – February 5, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment […]

Continue Reading
January 13, 2020

ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery

New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chem’s proprietary DNA Encoded Library technology (DEX™) for the […]

Continue Reading
September 4, 2019

Maruho and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – September 4, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Maruho Co., Ltd. (Maruho) to discover lead compounds for novel and challenging targets […]

Continue Reading
May 27, 2019

Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry.

May 27, 2019|Molecules|Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry Inspired by the many reported successful applications of DNA-encoded chemical libraries in drug discovery projects with protein targets, we decided to apply this platform to nucleic acid targets. We used a 120-billion-compound set of 33 distinct DNA-encoded chemical libraries and affinity-mediated selection to […]

Continue Reading
January 4, 2019

X-Chem and Vertex Expand Existing Partnership

WALTHAM, Mass. – January 4, 2019 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).

Continue Reading
December 19, 2018

X-Chem Enters Strategic Collaboration with Bristol-Myers Squibb

WALTHAM, Mass. – December 18, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb.

Continue Reading
December 12, 2018

Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration

WALTHAM, Mass. – December 12, 2018 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications.

Continue Reading